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Introduction: Alzheimer’s disease (AD) is a progressive neurodegenerative 
condition of the central nervous system among old people. AD is characterized by 
two neuropathological hallmarks: Extracellular senile plaque deposits, composed of 
amyloid beta (Aβ), and Intracellular neurofibrillary tangles (NFTs), made of 
truncated and hyperphosphorylated tau. Previous studies suggest that Asparagine 
Endopeptidase (AEP), a lysosomal cysteine proteinase, is activated during aging 
process. It proteolytically degrades tau and abolishes its microtubule assembly 
function, induces tau aggregation and triggers neurodegeneration. 
Methods and Results: Therefore, AEP is an attractive target of drug discovery 
against AD. In this study, we investigated the important pharmacophore feature 
required for inhibitors of AEP by generating a structure-based pharmacophore model 
followed by virtual screening and subsequent validation by molecular docking. The 
computational findings discussed in our study provide initial information of 
inhibitory effects of ligand, (ZINC3979524), over AEP. 
Conclusions: VS of the ZINC database against AEP led to select some good 
inhibitors for the treatment of Alzheimer’s disease. Therefore, this study can be a 
good starting point for in vitro and in vivo experimental studies and can establish as 
a novel therapeutic agent against AD 
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